Quanome Technologies Secures Insider-Funded Revolving Credit Facility
TipRanks (Thu, 1-Oct 4:29 PM ET)
Quanome CEO to Back Quantum Strategy with Up to $15 Million in Non-Dilutive Growth Capital
Globe Newswire (Thu, 1-Oct 9:25 AM ET)
Quanome Advances Its AI Cloud Business XDT with US$18.8 Million Infrastructure Purchase Agreement
Globe Newswire (Wed, 23-Sep 8:45 AM ET)
Quanome Technologies Establishes Global Quantum Council and Scientific Advisory Network
Globe Newswire (Thu, 20-Aug 10:27 AM ET)
Globe Newswire (Wed, 5-Aug 1:00 PM ET)
Quanome Technologies Inc operates in the midstream segment of the pharmaceutical industrial ecosystem, operating between upstream pharmaceutical manufacturers and downstream medical end customers. It sources products from multiple manufacturers and suppliers, and distribute them to hospitals, pharmaceutical distributors and other healthcare providers. Its principal product categories include infusion products, foods for special medical purposes, and specialty pharmaceuticals. It operates in one reportable segment serves its customers by providing pharmaceutical products in China. The company generates a substantial percentage of its revenue from selling pharmaceutical products on a direct basis.
Quanome Technologies trades on the NASDAQ stock market under the symbol QNME.
As of October 2, 2026, QNME stock price climbed to $0.56 with 617,123 million shares trading.
QNME has a market cap of $19.28 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that QNME belongs to (by Net Assets): VXF.
QNME support price is $.46 and resistance is $.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QNME shares will trade within this expected range on the day.